Table 1. Characteristics of Included Studies.
Source | Cohort studies | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Database | Study period | No. of participants, AD/non-AD | Age, mean (SD), y | Sex, female % | Definition of AD | VTE, HRs (95% CI) | VTE incidence rates per 100 patient-years | |||||||
Meyers et al,21 2021 | IBM MarketScan Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases | 2012-2017 | 198 685/198 685 | 46.0 (17.0) | 65.2 | ICD-9 code 691.8 or ICD-10 code L20.0, L20.8x, L20.9 | 0.77 (0.69-0.85) | 0.24 | ||||||
Schneeweiss et al,22 2021 | Optum’s deidentified Clinformatics Data Mart Database | 2004-2019 | 30 418/30 418 | 47.5 (18.0) | 60.8 | ICD-9 code 691.8 or ICD-10 code L20, L20.82, L20.84 | 1.19 (0.95-1.48) | 0.18 | ||||||
Source | Randomized clinical trials | |||||||||||||
Clinical trial identifier | JAK inhibitor | No. of patients with AD, intervention group/control group | Age, mean (SD), y | Sex, female % | Definition of AD | Placebo-controlled phase, weeks | ||||||||
Bieber et al,23 2021 | NCT03720470 (JADE COMPARE) | Abrocitinib | 464/131 | 38.0 (14.7) | 51.7 | Hanifin and Rajka criteria | 12 | |||||||
Blauvelt et al,24 2021 | NCT03738397 (Heads up) | Upadacitinib | 348/344 | 36.6 (14.6) | 47.4 | Hanifin and Rajka criteria | 24 | |||||||
Blauvelt et al,24 2022 | NCT03627767 (JADE REGIMEN) | Abrocitinib | 531/267 | Median (IQR), 29.0 (20-41) | 43.9 | Hanifin and Rajka criteria | 40 | |||||||
Eichenfield et al,26 2021 | NCT03796676 (JADE TEEN) | Abrocitinib | 189/96 | Median (IQR), 16.0 (14-17) | 46.6 | Hanifin and Rajka criteria | 12 | |||||||
Gooderham et al,27 2019 | NCT02780167 | Abrocitinib | 211/56 | 40.4 (16.3) | 51.7 | Hanifin and Rajka criteria | 12 | |||||||
Guttman-Yassky et al,28 2020 | NCT02925117 | Upadacitinib | 126/40 | 40.0 (15.3) | 36.5 | Hanifin and Rajka criteria | 16 | |||||||
Guttman-Yassky et al,29 2021 | NCT03569293 (Measure Up 1) and NCT03607422 (Measure Up 2) | Upadacitinib | 1124/559 | Median (IQR), 33.8 (12-75) | 44.0 | Hanifin and Rajka criteria | 16 | |||||||
Katoh et al,30 2022 | NCT03661138 (Rising Up) | Upadacitinib | 182/90 | 35.5 (13.0) | 24.7 | Hanifin and Rajka criteria | 24 | |||||||
Reich et al,31 2020 | NCT03733301 (BREEZE-AD7) | Baricitinib | 220/108 | 33.9 (12.1) | 34.1 | Diagnostic criteria proposed by AAD guideline | 16 | |||||||
Reich et al,32 2021 | NCT03568318 (AD Up) | Upadacitinib | 597/303 | Median (IQR), 34.0 (12-74) | 38.2 | Hanifin and Rajka criteria | 16 | |||||||
Silverberg et al,33 2020 | NCT03575871 (JADE MONO-2) | Abrocitinib | 313/78 | 35.5 (15.3) | 41.9 | Hanifin and Rajka criteria | 12 | |||||||
Simpson et al,34 2020 | NCT03349060 (JADE MONO-1) | Abrocitinib | 310/77 | 32.8 (16.4) | 44.8 | Hanifin and Rajka criteria | 12 | |||||||
Simpson et al,35 2020 (Simpson 2020a) | NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2) | Baricitinib | 745/493 | 35.0 (12.8) | 37.0 | Diagnostic criteria proposed by AAD guideline | 16 | |||||||
Simpson et al,36 2021 (Simpson 2020b) | NCT03435081 (BREEZE-AD5) | Baricitinib | 292/146 | 40.0 (16.0) | 50.9 | Diagnostic criteria proposed by AAD guideline | 16 | |||||||
Zhao et al,37 2021 | NCT04162899 | SHR0302 | 70/35 | 36.9 (14.8) | 38.6 | Chinese criteria | 12 |
Abbreviations: AAD, American Academy of Dermatology; AD, atopic dermatitis; HR, hazard ratio; ICD, International Classification of Diseases; VTE, venous thromboembolism.